HER2 阳性乳腺癌的新临床亚型：异质性扩增？
Heterogeneous Amplification-a New Clinical Category of HER2-Positive Breast Cancer?
机构信息
The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom.
出版信息
Cancer Discov. 2021 Oct;11(10):2369-2371. doi: 10.1158/2159-8290.CD-21-0936.
PMID:34598949
Abstract
amplification heterogeneity is associated with resistance to trastuzumab emtansine in the neoadjuvant setting, emphasizing the importance of assessing whether heterogeneous HER2-positive cancers require different treatment pathways..
摘要
扩增异质性与曲妥珠单抗-美坦新偶联物在新辅助治疗环境中的耐药性相关，强调了评估HER2 阳性癌症是否存在异质性是否需要不同治疗途径的重要性。
Zotero 插件